These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 26309036)

  • 21. Jadomycins derived from the assimilation and incorporation of norvaline and norleucine.
    Dupuis SN; Veinot T; Monro SM; Douglas SE; Syvitski RT; Goralski KB; McFarland SA; Jakeman DL
    J Nat Prod; 2011 Nov; 74(11):2420-4. PubMed ID: 22050382
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of the cytotoxic activity of new jadomycin derivatives reveals the potential to improve its selectivity against tumor cells.
    Fan K; Zhang X; Liu H; Han H; Luo Y; Wang Q; Geng M; Yang K
    J Antibiot (Tokyo); 2012 Sep; 65(9):449-52. PubMed ID: 22714025
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterization of the DNA-binding domain and identification of the active site residue in the 'Gyr A' half of Leishmania donovani topoisomerase II.
    Sengupta T; Mukherjee M; Das R; Das A; Majumder HK
    Nucleic Acids Res; 2005; 33(8):2364-73. PubMed ID: 15860773
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characterization of the human topoisomerase IIbeta (TOP2B) promoter activity: essential roles of the nuclear factor-Y (NF-Y)- and specificity protein-1 (Sp1)-binding sites.
    Lok CN; Lang AJ; Mirski SE; Cole SP
    Biochem J; 2002 Dec; 368(Pt 3):741-51. PubMed ID: 12197834
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Copper-mediated nuclease activity of jadomycin B.
    Monro SM; Cottreau KM; Spencer C; Wentzell JR; Graham CL; Borissow CN; Jakeman DL; McFarland SA
    Bioorg Med Chem; 2011 Jun; 19(11):3357-60. PubMed ID: 21565515
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Culture conditions improving the production of jadomycin B.
    Jakeman DL; Graham CL; Young W; Vining LC
    J Ind Microbiol Biotechnol; 2006 Sep; 33(9):767-72. PubMed ID: 16568271
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization of DNA topoisomerase II alpha/beta heterodimers in HeLa cells.
    Gromova I; Biersack H; Jensen S; Nielsen OF; Westergaard O; Andersen AH
    Biochemistry; 1998 Nov; 37(47):16645-52. PubMed ID: 9843432
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the E2F-1/DP-1 transcription factor complex.
    Hofland K; Petersen BO; Falck J; Helin K; Jensen PB; Sehested M
    Clin Cancer Res; 2000 Apr; 6(4):1488-97. PubMed ID: 10778981
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A distinct subnuclear localization of mammalian DNA topoisomerase IIbeta in yeast.
    Sakaguchi A; Akashi T; Kikuchi A
    Biochem Biophys Res Commun; 2001 May; 283(4):876-82. PubMed ID: 11350066
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Indeno[1,2-c]isoquinolin-5,11-diones conjugated to amino acids: Synthesis, cytotoxicity, DNA interaction, and topoisomerase II inhibition properties.
    Ahn G; Lansiaux A; Goossens JF; Bailly C; Baldeyrou B; Schifano-Faux N; Grandclaudon P; Couture A; Ryckebusch A
    Bioorg Med Chem; 2010 Nov; 18(22):8119-33. PubMed ID: 20961767
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design and synthesis of heterobimetallic topoisomerase I and II inhibitor complexes: in vitro DNA binding, interaction with 5'-GMP and 5'-TMP and cleavage studies.
    Arjmand F; Muddassir M
    J Photochem Photobiol B; 2010 Oct; 101(1):37-46. PubMed ID: 20638859
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterization of l-Digitoxosyl-phenanthroviridin from Streptomyces venezuelae ISP5230.
    Robertson AW; Martinez-Farina CF; Syvitski RT; Jakeman DL
    J Nat Prod; 2015 Aug; 78(8):1942-8. PubMed ID: 26203536
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Structural basis of type II topoisomerase inhibition by the anticancer drug etoposide.
    Wu CC; Li TK; Farh L; Lin LY; Lin TS; Yu YJ; Yen TJ; Chiang CW; Chan NL
    Science; 2011 Jul; 333(6041):459-62. PubMed ID: 21778401
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cytotoxic mechanism of XK469: resistance of topoisomerase IIbeta knockout cells and inhibition of topoisomerase I.
    Snapka RM; Gao H; Grabowski DR; Brill D; Chan KK; Li L; Li GC; Ganapathi R
    Biochem Biophys Res Commun; 2001 Feb; 280(4):1155-60. PubMed ID: 11162648
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Drug sensitivity and sequence specificity of human recombinant DNA topoisomerases IIalpha (p170) and IIbeta (p180).
    Cornarotti M; Tinelli S; Willmore E; Zunino F; Fisher LM; Austin CA; Capranico G
    Mol Pharmacol; 1996 Dec; 50(6):1463-71. PubMed ID: 8967966
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Human topoisomerase IIalpha and IIbeta interact with the C-terminal region of p53.
    Cowell IG; Okorokov AL; Cutts SA; Padget K; Bell M; Milner J; Austin CA
    Exp Cell Res; 2000 Feb; 255(1):86-94. PubMed ID: 10666337
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Jadomycin breast cancer cytotoxicity is mediated by a copper-dependent, reactive oxygen species-inducing mechanism.
    Hall SR; Blundon HL; Ladda MA; Robertson AW; Martinez-Farina CF; Jakeman DL; Goralski KB
    Pharmacol Res Perspect; 2015 Mar; 3(2):e00110. PubMed ID: 25729577
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Conditions for the production of jadomycin B by Streptomyces venezuelae ISP5230: effects of heat shock, ethanol treatment and phage infection.
    Doull JL; Singh AK; Hoare M; Ayer SW
    J Ind Microbiol; 1994 Mar; 13(2):120-5. PubMed ID: 7764672
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Specificity protein 1 regulates topoisomerase IIβ expression in SH-SY5Y cells during neuronal differentiation.
    Guo H; Cao C; Chi X; Zhao J; Liu X; Zhou N; Han S; Yan Y; Wang Y; Xu Y; Yan Y; Cui H; Sun H
    J Neurosci Res; 2014 Oct; 92(10):1374-83. PubMed ID: 24801450
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Topoisomerase II DNA cleavage stimulation, DNA binding activity, cytotoxicity, and physico-chemical properties of 2-aza- and 2-aza-oxide-anthracenedione derivatives.
    De Isabella P; Palumbo M; Sissi C; Capranico G; Carenini N; Menta E; Oliva A; Spinelli S; Krapcho AP; Giuliani FC
    Mol Pharmacol; 1995 Jul; 48(1):30-8. PubMed ID: 7623772
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.